Feds charge Osiris ex­ecs with cook­ing the books as stock price soared

In­vestors might re­mem­ber how in­ter­est in the stock of the lit­tle re­gen­er­a­tive med biotech Osiris Ther­a­peu­tics $OSIR hit a fever pitch in the sum­mer of 2015, with shares top­ping $21 as CEO Lode De­bra­ban­dere tout­ed a 78% spike in rev­enue, com­pared to the same pe­ri­od in 2014. The com­pa­ny was staffing up, in­tro­duc­ing a new prod­uct and was on a roll, by his ac­count.

But the SEC said late Thurs­day that a sig­nif­i­cant part of their suc­cess was an il­lu­sion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER